E3 PreliminaryModerate confidencePEM not requiredMechanisticPeer-reviewedMachine draft
Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.
Felger, J C, Cole, S W, Pace, T W W et al. · Psychological medicine · 2012 · DOI
Quick Summary
When patients received interferon-alpha treatment (used for hepatitis C and cancer), researchers looked at immune cell genes to understand why the treatment causes depression and fatigue. They found that one gene called OAS2, previously linked to chronic fatigue syndrome, was especially active in patients who developed depression and fatigue during treatment. This suggests that immune system changes may directly contribute to these symptoms.
Why It Matters
This study identifies OAS2 as a potential molecular link between immune activation and both depression and fatigue—symptoms central to ME/CFS. By demonstrating that immune cytokine signaling alters gene expression patterns associated with these symptoms, the research supports the biological plausibility of immune mechanisms in ME/CFS and provides candidate genes for future investigation.
Observed Findings
- OAS2 gene expression correlated with depression scores (r=0.80, p=0.003) and fatigue scores (r=0.70, p=0.017) at 12 weeks of IFN-α treatment.
- IFN-α treatment upregulated 252 gene transcripts and downregulated 116 transcripts in PBMCs.
- Patients with high depression/fatigue showed upregulation of genes with promoter motifs for myeloid differentiation, interferon, and AP-1 signaling, and reduced CREB/ATF motifs.
- Gene expression changes were primarily derived from monocytes and plasmacytoid dendritic cells.
Inferred Conclusions
- OAS2, a gene previously linked to CFS, is a specific molecular marker of IFN-α-induced depression and fatigue.
- Alteration of CREB/ATF transcriptional control may be a key mechanism linking immune activation to depression.
- Immune-mediated changes in peripheral blood cell gene expression contribute to both depression and fatigue during chronic interferon administration.
Remaining Questions
- Does OAS2 elevation occur in drug-naive ME/CFS patients, or is it specific to IFN-α-induced illness?
- Are the CREB/ATF pathway changes reversible after IFN-α treatment ends, and do they predict symptom recovery?
- Which downstream genes regulated by altered transcription factors actually drive the depression and fatigue phenotype?
What This Study Does Not Prove
This study does not prove that OAS2 elevation causes depression and fatigue; it only shows correlation. The findings are from IFN-α-induced symptoms in hepatitis C patients, not ME/CFS patients, so whether the same mechanisms drive ME/CFS remains unknown. The small sample and 12-week timeframe do not establish whether these gene changes persist or are specific to IFN-α-induced illness.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:CytokinesGene ExpressionBlood Biomarker
Method Flag:No ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1017/S0033291711002868
- PMID
- 22152193
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →